This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ciccolini, J. Articles by Iliadis, A. Search for Related Content PubMed PubMed Citation Articles by Ciccolini, J. Articles by Iliadis, A.

Laboratoire de Toxicocinétique et Pharmacocinétique, Faculté de Pharmacie, 13385 Marseille [J. C., S. G., C. A., A. I.]; Laboratoire de Toxicologie, Faculté de Pharmacie, 34000 Montpellier [P. C., A. E., J-P. C.]; and Cancérologie Experimentale, Centre Regional de Lutte contre le Cancer Val d’Aurelle, 34000 Montpellier [A. P.], France

We reported previously that 5-fluorouracil (FUra) efficacy could be enhanced by increasing tumoral thymidine phosphorylase (TP) activity. Potentiated TP yield was achieved by either transfecting cells with human TP gene (A. Evrard et al., Br. J. Cancer, 80: 1726–1733, 1999) or associating FUra with 2'-deoxyinosine (d-Ino), a modulator providing the tumors with TP cofactor deoxyribose 1-phosphate (J. Ciccolini et al., Clin. Cancer Res., 6: 1529–1535, 2000). The purpose of the present work was to study the effects of a combined modulation (TP gene transfer + use of d-Ino) on the sensitivity to FUra of the LS174T human colorectal cell line. Results showed a near 4000 times increase of cell sensitivity in vitro after double (genetic + biochemical) modulation. This potentiation of tumor response was accompanied by a total change in the FUra anabolic pathway with a 5000% increase of cytosolic fluorodeoxyuridine monophosphate, a stronger and longer inhibition of thymidylate synthase, and 300% augmentation of DNA damage. Besides, whereas thymidine failed to inhibit FUra cytotoxicity in LS174T wild-type cells, the potentiation of the antitumor activity observed in the modulating regimen was partly reversed by thymidine, indicative of thymidylate synthase as the main drug target. The impact of this double modulation was next investigated in xenograft-bearing nude mice. Results showed that whereas FUra alone was completely ineffective on wild-type tumor growth, the size of TP-transfected tumors in animals treated with the FUra/d-Ino combination was reduced by 80% (P < 0.05). Our results suggest that FUra exhibits stronger antiproliferative activity when activated via TP through the DNA pathway and that high tumoral TP activity therefore leads to enhanced sensitivity to fluoropyrimidines.

This article has been cited by other articles:

				N. Magne, J.-L. Fischel, A. Dubreuil, P. Formento, J. Ciccolini, J.-L. Formento, C. Tiffon, N. Renee, S. Marchetti, M.-C. Etienne, et al. ZD1839 (Iressa) Modifies the Activity of Key Enzymes Linked to Fluoropyrimidine Activity: Rational Basis for a New Combination Therapy with Capecitabine Clin. Cancer Res., October 15, 2003; 9(13): 4735 - 4742. [Abstract] [Full Text] [PDF]

				A. Alimonti, G. Ferretti, S. Di Cosimo, F. Cognetti, and A. Vecchione Can Colorectal Cancer Patients With Thymidylate Synthase-Overexpressing Liver Metastases Have an Overall Survival Advantage With Hepatic Arterial Infusion Alone? J. Clin. Oncol., September 15, 2003; 21(18): 3543 - 3544. [Full Text] [PDF]

				J. Ciccolini, F. Fina, K. Bezulier, S. Giacometti, M. Roussel, A. Evrard, P. Cuq, S. Romain, P.-M. Martin, and C. Aubert Transmission of Apoptosis in Human Colorectal Tumor Cells Exposed to Capecitabine, Xeloda, Is Mediated via Fas Mol. Cancer Ther., September 1, 2002; 1(11): 923 - 927. [Abstract] [Full Text] [PDF]